BTK inhibitorsWaldenström macroglobulinaemialymphoplasmacytic lymphomaDLBCLactivated B-cell-type diffuse large B-cell lymphoma (DLBCL)IgM monoclonal gammopathy
…val in DLBCL. Therapeutically, MYD88 L265P predicts response to BTK inhibitors in WM, although concurrent CXCR4 mutations attenuate treatment …